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Objective: Mirabegron, a b3-adrenoceptor agonist, has been shown to be effective and safe in the
treatment of overactive bladder (OAB). The aim of this study was to assess the efﬁcacy and safety of
mirabegron (50 mg) versus placebo in Taiwanese patients with OAB.
Materials and patients: This was a multicenter, randomized, double-blind, parallel-group, placebo- and
active-controlled trial conducted at 12 sites in Taiwan. Patients were randomized in a 1:1:1 ratio to
receive placebo, mirabegron (50 mg), or tolterodine extended release (4 mg) orally once daily for 12
weeks. The primary efﬁcacy end point was the change in the mean number of micturitions per 24 hours
from baseline to the ﬁnal visit. Secondary end points were volume voided, and the number of urgency,
urinary incontinence, urge incontinence, and nocturia episodes per 24 hours; in addition, the King's
Health Questionnaire (KHQ) was administered to assess effects on quality of life.
Results: A total of 218 patients were included in the full analysis set (68 in the placebo group; 76 in the
mirabegron group; and 74 in the tolterodine group). The adjusted mean difference between the mir-
abegron and placebo groups for the change in mean number of micturitions per 24 hours was 1.42
(p ¼ 0.004). The adjusted mean difference between the mirabegron and placebo groups with regard to
the change in volume voided per micturition was 16.7 mL (p ¼ 0.013). However, the mirabegron group
did not show statistically signiﬁcant superiority to the placebo group in the other efﬁcacy variables.
There was also no statistically signiﬁcant difference between mirabegron and placebo in any KHQ
domain score. The incidence of treatment-emergent adverse events in the mirabegron group was low
and similar to that in the placebo group.ddhist Tzu Chi General Hospital, Number 707, Section 3, Chung-Yang Road, Hualien 970, Taiwan.
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H.-C. Kuo et al. / Urological Science 26 (2015) 41e4842Fig. 1. The study design.Conclusion: Mirabegron at a dose of 50 mg once daily for 12 weeks is superior to placebo in reducing the
frequency of micturitions in Taiwanese patients with symptoms of OAB. No clinically relevant, serious
adverse events were identiﬁed.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Overactive bladder (OAB) syndrome is characterized by urinary
urgency with or without urgency incontinence,1 which affects >
400 million people worldwide.2 Epidemiology studies have also
revealed that OAB affects 12e16% of the adult population across
Europe, the USA, and Japan.3e5 Antimuscarinics have been
considered the ﬁrst-line pharmacotherapy for OAB.6e8 However, a
high proportion of patients discontinue antimuscarinic therapy dueFig. 2. Disposition of the study pto suboptimal efﬁcacy or intolerable adverse events (AEs) with <
25% remaining on treatment at 1 year.9,10 There is therefore an
urgent need to develop new drugs for OAB that do not have the
adverse effects of antimuscarinic agents.
The b3-adrenergic receptors have been known to promote urine
storage in the bladder by inducing detrusor relaxation in animal
and human bladders.11e13 The b3-adrenoceptor is the predominant
b-receptor subtype in the human urinary bladder, representing 97%
of total b-adrenoceptor messenger RNA expression in the human
bladder.14 The b3-adrenoceptor agonists relax the detrusor smooth
muscle during the bladder storage phase and increase bladder ca-
pacity.15 Unlike the mechanism of antimuscarinic agents, b3-adre-
noceptor agonists increase bladder capacity without a change in
micturition pressure, residual volume, or voiding contraction.16e18
Mirabegron, a b3-adrenoceptor agonist, is a ﬁrst-in-class drug
for the treatment of OAB.19 Mirabegron demonstrated signiﬁcant
dose-dependent improvements in key OAB symptoms in one phase
II study.20 Pooled safety data indicated that mirabegron may be a
valuable treatment option for patients with OAB as the incidence of
dry mouth, the chief cause of discontinuation of antimuscarinic
agents, was lower than with the use of an active comparator, tol-
terodine extended release (ER; 4 mg).21
Although recent phase III trials have conﬁrmed the efﬁcacy and
safety of mirabegron in treatment of OAB in European, Australian,
North American, and Japanese populations,22e25 the therapeutic
efﬁcacy and safety had not been demonstrated in Taiwanese
people. This phase III study aims to assess the efﬁcacy ofatients. QOL ¼ quality of life.
Table 1
Demographic and baseline characteristics in Taiwanese overactive bladder patients
(FAS).
Placebo
(n ¼ 68)
Mirabegron
(50 mg)
(n ¼ 76)
Tolterodine ER
(4 mg)
(n ¼ 74)
Sex, n (%)
Female 42 (61.8) 47 (61.8) 44 (59.5)
Age (y), mean (SD) 58.4 (13.0) 59.0 (15.1) 56.4 (15.8)
n (%) by age group
< 65 y 46 (67.6) 44 (57.9) 48 (64.9)
 65 y 22 (32.4) 32 (42.1) 26 (35.1)
Weight (kg), mean (SD) 62.7 (10.2) 62.0 (10.8) 62.6 (12.8)
Type of incontinence n (%), mean (SD)
No incontinence 14 (20.6) 17 (22.4) 17 (23.0)
Urgency incontinence 38 (55.9) 40 (52.6) 42 (56.8)
Mixed stress/urgency
incontinence
16 (23.5) 19 (25.0) 15 (20.3)
Duration of OAB symptoms (mo)
Mean (SD) 52.7 (75.1) 48.6 (48.8) 47.6 (48.3)
Range 3e430 4e249 3e256
Number of
Micturitions/24 h,
mean (SD)
13.2 (5.3) 11.6 (3.1) 12.3 (3.3)
Urgency episodes/24 h,
mean (SD)
5.5 (4.3) 5.5 (4.0) 5.9 (4.9)
Incontinence episodes/24 h,
mean (SD)
2.6 (2.2) 2.5 (3.0) 1.6 (2.0)
Urgency incontinence/24
h, mean (SD)
2.7 (2.4) 2.2 (2.4) 1.6 (2.1)
Nocturia episodes/night,
mean (SD)
2.7 (1.7) 2.3 (1.4) 2.4 (1.5)
Volume voided/micturition
(mL), mean (SD)
150.1 (63.4) 152 (54.3) 148 (60.7)
King's Health Questionnaire
General health perception 40.6 (19.2) 43.5 (21.7) 46.5 (24.0)
Incontinence impact 75.5 (25.4) 78.5 (25.7) 83.1 (19.4)
Role limitation 46.6 (31.7) 50.5 (31.5) 50.5 (30.5)
Physical limitation 46.4 (32.7) 53.4 (30.0) 54.9 (32.5)
Social limitation 31.4 (29.8) 33.9 (31.7) 36.2 (33.4)
Personal relationships 21.2 (28.9) 23.3 (30.2) 32.4 (38.5)
Emotions 46.5 (29.4) 53.6 (29.6) 56.2 (33.1)
Sleep/energy 45.3 (28.2) 51.8 (28.0) 52.4 (29.6)
Severity measures 26.9 (18.5) 32.6 (23.3) 34.7 (23.8)
Bladder problems 29.7 (12.8) 32.7 (14.0) 33.5 (13.7)
ER ¼ extended release; FAS ¼ full analysis set; OAB ¼ overactive bladder;
SD ¼ standard deviation.
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people with symptoms of OAB. The efﬁcacy and safety ofTable 2
Changes of measured variables from baseline to the last visit in Taiwanese overactive bla
Treatment group n Baseline L
Micturitions/24 h Placebo 68 13.2 (5.29) 1
Mirabegron (50 mg) 76 11.6 (3.09) 9
Tolterodine 74 12.3 (3.27) 1
Incontinence/24 h Placebo 24 2.61 (2.18) 2
Mirabegron (50 mg) 33 2.54 (3.00) 1
Tolterodine 26 1.58 (1.95) 0
Urgency episodes/24 h Placebo 68 5.49 (4.30) 4
Mirabegron (50 mg) 76 5.53 (3.98) 3
Tolterodine 74 5.93 (4.87) 3
Urge incontinence/24 h Placebo 17 2.67 (2.36) 1
Mirabegron (50 mg) 25 2.16 (2.42) 0
Tolterodine 19 1.61 (2.10) 0
Volume voided/24 h Placebo 67 150 (63.4)
Mirabegron (50 mg) 75 152 (54.3)
Tolterodine 74 148 (60.7)
Nocturia episode/24 h Placebo 65 2.66 (1.73) 2
Mirabegron (50 mg) 73 2.32 (1.38) 1
Tolterodine 71 2.35 (1.51) 1
FAS ¼ full analysis set; SD ¼ standard deviation; SE ¼ standard error.
a Adjusted change from baseline results are generated from the analysis of covariancemirabegron were also compared with tolterodine sustained
release (SR; 4 mg qd), the reference drug, without a noninferiority
test. We also compared the results of this study with clinical trials
in other regions of the world.2. Materials and patients
2.1. Study design and participants
This 12-week multinational and multicenter, randomized,
double-blind, parallel-group, placebo- and active-controlled trial
was conducted at 12 sites in Taiwan. The study population con-
sisted of men and women over the age of 18 years with symptoms
of OAB for > 3 months. The study-drug-administration period
consists of 14weeks in total including 2weeks for administration of
the placebo for the run-in period and 12 weeks for administration
of the study drug for the treatment period (Fig.1). Patients whomet
the inclusion criteria and did not violate the exclusion criteria were
randomized to receive the study drug [mirabegron (50 mg), tol-
terodine (4 mg), or placebo] orally, once a day after breakfast, for 12
weeks.
The patients were provisionally enrolled for randomization. The
inclusion and exclusion criteria are listed in Appendix 1. Medica-
tions that might affect lower urinary tract function were restricted,
such as a1-adrenoceptor antagonists, medication for diabetes
insipidus, antidepressants, 5a-reductase inhibitors, injection of
capsaicin or resiniferatoxin into the bladder, or injection of botu-
linum toxin into bladder muscles. After having fulﬁlled all selection
criteria at the end of the placebo run-in period (Visit 2), patients
were randomized to one of the three treatment groups in a 1:1:1
ratio to receive placebo, mirabegron (50 mg), or tolterodine ER
(4 mg) orally once daily for 12 weeks, using a computer-generated
randomization list. During the placebo run-in period, patients were
blinded to the identity of the study drug, and during the double-
blind treatment, both patients and investigators were blinded to
the identity of the randomized drug assignment.
All patients provided written informed consent. The study was
approved by the Institutional Review Board of each study site and
conducted in accordance with the ethical principles of the Decla-
ration of Helsinki, Good Clinical Practice, International Conference
on Harmonization guidelines, and all applicable laws and
regulations.dder patients (FAS).
ast visit Mean change
from baseline (SD)
Adjusted mean difference
vs. placebo (SE)a
p
1.9 (4.70) 1.28 (3.49)
.46 (2.79) 2.12 (2.91) 1.42 (0.48) 0.004
1.4 (3.79) 0.98 (3.18) 0.01 (0.48) 0.985
.03 (3.24) 0.58 (2.51)
.16 (2.51) 1.37 (3.72) 0.84 (0.63) 0.112
.78 (1.25) 0.79 (2.02) 0.95 (0.68) 0.756
.00 (4.37) 1.49 (4.84)
.56 (3.78) 1.97 (3.49) 0.46 (0.61) 0.446
.97 (4.53) 1.96 (4.33) 0.25 (0.61) 0.683
.65 (2.86) 1.02 (2.68)
.43 (1.09) 1.73 (2.71) 1.15 (0.55) 0.083
.63 (1.07) 0.98 (2.44) 0.86 (0.59) 0.592
156 (67.5) 5.54 (32.3)
173 (69.7) 22.17 (47.8) 16.70 (6.69) 0.013
161 (67.0) 13.30 (36.9) 7.59 (6.69) 0.258
.12 (1.47) 0.55 (1.54)
.82 (1.12) 0.50 (1.14) 0.13 (0.18) 0.484
.90 (1.30) 0.45 (1.25) 0.06 (0.18) 0.734
model with the treatment group as a ﬁxed factor and baseline as a covariate.
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The primary efﬁcacy end point was the change in the mean
number of micturitions per 24 hours from baseline to the ﬁnal visit.
The mean number of micturitions per 24 hours in the run-in period
was used as the baseline. The secondary efﬁcacy end points were
the changes from baseline to the ﬁnal visit in the mean number of
urgency episodes per 24 hours, mean number of urinary inconti-
nence episodes per 24 hours, mean number of urge incontinence
episodes per 24 hours, mean volume voided per micturition, and
mean number of nocturia episodes. An additional end point was the
individual domain scores of the King's Health Questionnaire (KHQ)
to assess effects on quality of life (QOL).2.3. Safety assessment
Safety assessments included reporting of AEs, clinical laboratory
assessments, vital signs, physical examination, electrocardiogram
ﬁndings, and measurement of postvoid residual (PVR) volume. An
independent cardiovascular adjudication committee determined
all deaths and serious potential cardiovascular AEs using the cate-
gorization of Antiplatelet Trialists' Collaboration/Major Adverse
Cardiovascular Events (APTC/MACE) or non-APTC/MACE.
All unfavorable signs and symptoms observed from the start of
the study medication for the run-in period to immediately before
administration of the study drug for the treatment period were
handled as AEs in the run-in period. Exacerbation of a complication
beyond the expected clinical course after initiation of the study
medication for the run-in period was included as an AE in the run-
in period. New AEs developed after administration of the studyFig. 3. Adjusted mean change from baseline at each visit in (A) the mean number of micturit
incontinence episodes per 24 hours; (D) the mean number of urgency episodes per 24 hou
number of nocturia episodes (full analysis set). * Statistically signiﬁcant treatment beneﬁt re
V ¼ visit.drug for the treatment period including the post-treatment period.
Exacerbation of the symptoms of OAB was not deﬁned as an AE in
this clinical study.
2.4. Statistical methodology
Efﬁcacy was assessed using the full analysis set (FAS), which
included all randomized patients who took at least one dose of the
study drug and had at least a baseline and one postbaseline
micturition measurement. The domains of the KHQ were evaluated
using the QOL analysis set. Safety analyses were performed on the
safety analysis set, consisting of all randomized patients who took
at least one dose of the study drug. Analysis was performed in these
populations based on the International Conference on Harmoni-
zation of Technical Requirements for Registration of Pharmaceuti-
cals for Human Use guidelines E3 and E9.
This study was a part of an Asian mirabegron trial conducted in
Taiwan, Korea, India, and China. The sample size for the Asian study
was reported elsewhere,26 which was decided with reference to the
dose ﬁnding study (Study 178-CL-045) conducted in Japan.
3. Results
3.1. Patients' demographic characteristics
A total of 384 patients were screened and 248 patients were
randomized into the placebo (n ¼ 81), mirabegron (50 mg; n ¼ 85),
and tolterodine SR (4 mg; n ¼ 82) groups. The disposition of pa-
tients is shown in Fig. 2. Of the 248 randomized patients, 218 pa-
tients (68 in the placebo, 76 in the mirabegron, and 74 in theions per 24 hours; (B) the mean volume voided per micturition; (C) the mean number of
rs; (E) the mean number of urgency incontinence episodes per 24 hours; (F) the mean
lative to placebo (p < 0.05) at different time points. BL ¼ baseline; EOS ¼ end of study;
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mographics at baseline are presented in Table 1. In the FAS, no
statistically signiﬁcant imbalance across the three treatment
groups was found in any demographic characteristics. The per-
centage of females ranged from 59.5% to 61.8%. The majority of
patients in all treatment groups were aged < 65 years (57.9e67.6%).
The mean weights were similar among treatment groups.
Among the patient population, over two thirds had a history of
previous drug medication for OAB. No signiﬁcant difference was
noted among the three groups. The mean duration of OAB symp-
toms was 52.7 months, 48.6 months, and 47.6 months in the pla-
cebo, mirabegron, and tolterodine groups, respectively. The
majority of the patients in each group took the double-blind study
drug for at least 84 days.3.2. Efﬁcacy
Table 2 shows the changeof efﬁcacy variables frombaseline to the
ﬁnal visit. The mean number of micturitions per 24 hours decreased
in all treatment groups. The adjusted mean difference between the
mirabegron and placebo groups was 1.42, which was statistically
signiﬁcant (p ¼ 0.004). The adjusted mean difference between the
mirabegron and tolterodine groups was 1.41. The mirabegron
group demonstrated greater reduction in the mean number of mic-
turitions per 24 hours from baseline to the last visit compared with
the tolterodine group. No statistically signiﬁcant difference was
found between the tolterodine and placebo groups (p ¼ 0.985).
The mirabegron group demonstrated a statistically signiﬁcant
greater reduction in the mean number of micturitions per 24 hours
compared with the placebo group as early as Week 4 (p ¼ 0.017),
and efﬁcacy was maintained throughout the treatment period
(Weeks 8 and 12; p ¼ 0.050 and p ¼ 0.009, respectively). There was
also greater reduction in the mean number of micturitions per 24Table 3
Changes in the domain score (quality of life scores) in the King's Health Questionnaire fr
Treatment group n Baseline L
General health perception Placebo 64 40.6 (19.2) 4
Mirabegron 73 43.5 (21.7) 3
Tolterodine 71 46.5 (24.0) 4
Incontinence impact Placebo 64 75.5 (25.4) 6
Mirabegron 73 78.5 (25.7) 7
Tolterodine 71 83.1 (19.4) 6
Role limitation Placebo 64 46.6 (31.7) 3
Mirabegron 73 50.5 (31.5) 3
Tolterodine 71 50.5 (30.5) 4
Physical limitation Placebo 64 46.4 (32.7) 4
Mirabegron 73 53.4 (30.0) 4
Tolterodine 71 54.9 (32.5) 4
Social limitation Placebo 64 31.4 (29.8) 2
Mirabegron 73 33.9 (31.7) 2
Tolterodine 71 36.2 (33.4) 3
Personal relationships Placebo 48 21.2 (28.9) 2
Mirabegron 55 23.3 (30.2) 2
Tolterodine 54 32.4 (38.5) 2
Emotions Placebo 64 46.5 (29.4) 4
Mirabegron 73 53.6 (29.6) 3
Tolterodine 71 56.2 (33.1) 4
Sleep/energy Placebo 64 45.36 (28.2) 3
Mirabegron 73 51.8 (28.0) 3
Tolterodine 71 52.4 (29.6) 4
Severity measures Placebo 64 26.9 (18.5) 2
Mirabegron 73 32.6 (23.3) 2
Tolterodine 71 34.7 (23.8) 3
Bladder problems Placebo 64 29.7 (12.8) 2
Mirabegron 73 32.7 (14.0) 2
Tolterodine 71 33.5 (13.7) 2
QOL set ¼ quality of life analysis set; SD ¼ standard deviation; SE ¼ standard error.hours at Week 12 and at the last visit in the mirabegron group
compared with the tolterodine group (Fig. 3).
The mean changes in the mean volume voided per micturition
from baseline to the ﬁnal visit were 5.54 mL, 22.17 mL, and 13.30 mL
in the placebo, mirabegron, and tolterodine groups, respectively.
Thus, the mean volume voided per micturition increased in all
treatment groups. The adjusted mean difference between the mir-
abegron and placebo groups was 16.70 mL. The mirabegron (50 mg)
group demonstrated a statistically signiﬁcant greater increase in the
mean volume voided per micturition from baseline to the last visit
compared with placebo (p ¼ 0.013). The adjusted mean difference
between the tolterodine andplacebo groupswas 7.59mL (p¼ 0.258).
In the mirabegron group, an increase in the mean volume
voided per micturition was observed at Week 4, and the mean
volume voided per micturition subsequently continued to increase
until Week 12. Similar changes were also observed in the tolter-
odine group, but the degree of increase in the mean volume voided
per micturition was numerically larger in the mirabegron group
compared with the tolterodine group at all time points (Fig. 3).
There was no signiﬁcant difference between the mirabegron and
placebo groups, or between the tolterodine and placebo groups in
the mean change from baseline to the ﬁnal visit in incontinence
episodes, urgency episodes, urge incontinence episodes, or noctu-
ria episodes.
3.3. KHQ: QOL outcomes
All domain scores for the KHQ decreased from baseline to the
last visit in all treatment groups, which indicated improvement of
QOL. However, in any domain, no statistically signiﬁcant difference
was found between themirabegron and placebo groups for changes
in the scores from baseline to the last visit. In the mirabegron
group, scores for domains of role limitations, physical limitations,
emotions, and sleep/energy decreased by > 10 (Table 3).om baseline to the last visit in Taiwanese overactive bladder patients (QOL set).
ast visit Mean change from
baseline (SD)
Adjusted mean difference
vs. placebo (SE)
p
1.8 (20.4) 1.17 (22.5)
6.6 (21.3) 6.85 (24.0) 6.18 (3.35) 0.066
1.6 (21.1) 4.93 (25.2) 2.34 (3.38) 0.490
2.0 (29.6) 13.5 (30.1)
1.2 (28.5) 7.31 (28.5) 7.73 (4.60) 0.094
7.6 (29.8) 15.5 (29.2) 1.81 (4.66) 0.698
5.4 (27.6) 11.2 (32.9)
7.2 (33.7) 13.2 (35.5) 0.20 (4.73) 0.967
2.3 (34.4) 8.22 (25.6) 4.83 (4.81) 0.316
0.9 (30.7) 5.47 (29.4)
2.2 (30.8) 11.2 (32.3) 2.60 (4.49) 0.563
7.0 (33.0) 7.98 (26.7) 1.26 (4.53) 0.781
8.6 (27.6) 2.86 (27.3)
5.1 (25.5) 8.75 (29.6) 4.70 (3.83) 0.222
1.6 (29.7) 4.54 (24.3) 0.63 (3.86) 0.871
1.6 (23.2) 0.85 (25.9)
0.4 (30.0) 3.59 (28.7) 3.49 (4.80) 0.468
3.3 (30.2) 5.56 (24.9) 3.00 (4.82) 0.534
0.5 (30.7) 6.08 (24.6)
8.8 (29.1) 14.8 (31.6) 6.04 (4.22) 0.154
7.7 (33.4) 8.45 (23.9) 1.25 (4.26) 0.769
8.0 (26.5) 7.29 (25.5)
7.7 (26.4) 14.2 (29.4) 3.39 (3.83) 0.377
2.3 (25.0) 10.1 (25.6) 0.94 (3.86) 0.807
6.5 (20.4) 0.42 (16.2)
5.9 (20.2) 6.67 (16.3) 4.66 (2.59) 0.073
0.1 (24.7) 4.69 (16.1) 2.09 (2.62) 0.425
4.7 (14.6) 4.95 (15.8)
5.8 (16.7) 6.89 (16.0) 0.48 (2.42) 0.844
4.3 (15.4) 9.15 (14.8) 2.36 (2.44) 0.336
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The overall incidence of treatment-emergent AEs (TEAEs) was
42.9% (33/77 patients), 42.4% (36/85), and 49.4% (40/81) in the
placebo, mirabegron, and tolterodine groups, respectively. The
incidence was lower in the mirabegron group than in the other
treatment groups. There was no statistically signiﬁcant difference
in the incidence of TEAEs between the mirabegron group and the
other treatment groups. The TEAEs are presented in Table 4.
The incidence of serious TEAEs including death was one in the
placebo group and two serious AEs (SAEs) in the tolterodine group.
No drug-related SAE was reported in the mirabegron group. The
incidence of TEAEs leading to permanent discontinuation was 1.3%,
2.4%, and 1.2% in the placebo, mirabegron, and tolterodine groups,
respectively.
Most TEAEs were mild or moderate in severity in all treatment
groups. The most common TEAEs ( 2% of patients) in the mir-
abegron group were dry mouth (7.1%) and diarrhea (3.5%). The
incidence of these events in the mirabegron group was similar to
that in the placebo group. In themirabegron group, the incidence of
TEAEs of potential QTc prolongation, hypertension, urinary reten-
tion, potential syncope/seizure, potential glaucoma, and potential
hepatotoxicity was  0.5%. The incidence of TEAEs of potentialTable 4
Incidence of treatment-emergent adverse events and selected cardiovascular TEAEs
(SAF).
Placebo
(n ¼ 77)
Mirabegron
(50 mg)
(n ¼ 85)
Tolterodine
ER (4 mg)
(n ¼ 81)
No. of TEAEs (n) 68 76 117
Patients reporting
a TEAE (n)a
33 (42.9%) 36 (42.4%) 40 (49.4%)
Mild 31 (40.3%) 35 (41.2%) 33 (40.7%)
Moderate 1 (1.3%) 1 (1.2%) 2 (2.5%)
Severe 1 (1.3%) 0 5 (6.2%)
Most common TEAE ( 2% of patients), n (%)a
Dry mouth 3 (3.9%) 6 (7.1%) 7 (8.6%)
Diarrhea 1 (1.3%) 3 (3.5%) 2 (2.5%)
Drug-relatedb TEAE, (n) 36 29 58
Patients reporting a
drug-related
TEAE, n (%)a
19 (24.7%) 20 (23.5%) 24 (29.6%)
Dry mouth 2 (2.6%) 5 (5.9%) 7 (8.6%)
Urinary retention 0 0 0
Cardiovascular TEAEs (n) 10 6 9
TEAEs of potential QTc
prolongation (n) (%)
2 (2.6%) 1 (1.2%) 4 (4.9%)
Hypertension-related
TEAEs (n) (%)
0 2 (2.4%) 1 (1.2%)
TEAEs of potential
cardiac arrhythmia (n) (%)
7 (9.1%) 3 (3.5%) 4 (4.9%)
Deathsc 1 (1.3%) 0 0
SAE, n (%) 1 (1.3%) 0 2 (2.4%)
Drug-related SAE 0 0 0
TEAEs leading to
permanent
discontinuation of
the study drug n (%)
1 (1.3%) 2 (2.4%) 1 (1.2%)
Drug-related TEAE leading to
permanent
discontinuation
of the study drug, n (%)
1 (1.3%) 1 (1.2%) 0
ER ¼ extended release; SAE ¼ serious adverse event; SAF ¼ safety analysis set;
TEAE ¼ treatment-emergent adverse event.
a n (%) is the number of patients reporting a given event as a percentage of the
total number of patients in the treatment group.
b Drug relatedness was based on investigator assessment.
c Includes any death that occurred at any time after the ﬁrst dose of the study
drug, regardless of time after the last dose of the study drug.cardiac arrhythmia was 3.5%, which was lower than that in the
placebo group (9.1%). Changes in laboratory parameters were
similar across the treatment groups. No notable change from
baseline was found for the mean PVR in any treatment group
throughout the treatment period.
3.5. Comparison of end points between this study and different
mirabegron trials
Fig. 4 shows the changes in the efﬁcacy variables of the mir-
abegron arm from baseline to the last visit in this study in com-
parisonwith those in the mirabegron trials in Japan (Study No.178-
CL-048),25 the European Union (Study No. 178-CL-046),22 and the
United States (Study No. 178-CL-047).23 The micturition per 24
hours and the mean volume voided showed signiﬁcant improve-
ment among the four trials. The change of micturition per 24 hours
was the greatest in the Taiwanese data compared with the other
three trials. Compared with the results of the other three mirabe-
gron trials, the change of incontinence episodes in Taiwanese data
was higher than the Japanese trial (1.37 vs. 1.09); the change of
urgency episodes in Taiwanese data was greater than the Japanese
and U.S. trials (1.97 vs. 1.85 vs. 1.57, respectively); urge in-
continence episodes in Taiwanese data were higher than the Jap-
anese, European, and U.S. trials (1.73 vs.0.98 vs.1.33 vs. 1.32,
respectively); the mean volume voided in the Taiwanese data was
higher than in the U.S. trial (22.2 vs. 18.4); and the nocturia episode
was higher than in the Japanese trial (0.54 vs.0.45). However, in
these parameters, mirabegron did not show superior effect to
placebo as shown in the other three trials. Nevertheless, the safety
proﬁle of mirabegron in this trial was as good as that in the other
three trials.
4. Discussion
The results of this study conﬁrmed that mirabegron (50 mg) is
safe and effective in decreasing micturition frequency and
increasing the volume voided in Taiwanese people with OAB during
a 12-week treatment period.
Recently, three international phase III randomized controlled
trials of mirabegron have demonstrated statistically signiﬁcant
improvements in the decrease of episodes of frequency urgency
and urge incontinence compared with placebo.23e25 A pooled
analysis of these studies showed that mirabegron is well tolerated
and has a good safety proﬁle in patients with OAB.21 In a 12-month
safety and efﬁcacy study, mirabegronwas demonstrated to improve
key OAB symptoms from the ﬁrst measured time point of 4 weeks,
and the efﬁcacy was maintained throughout the 12-month treat-
ment period.24 In addition, patients treated with mirabegron
showed statistically signiﬁcant improvements in health-related
QOL measures versus placebo. The magnitude of the treatment
response is similar to that of other OAB agents.27
In this study, mirabegron (50 mg) showed statistically signiﬁ-
cant superiority to placebo with regard to the change in mean
number of micturition per 24 hours from baseline to the last visit in
Taiwanese patients. Mirabegron (50 mg) also showed statistically
signiﬁcant superiority to placebo in the change of mean volume
voided per micturition from baseline to the last visit. These results
were similar to those in trials of other regions such as Japan, the
European Union, and the United States. Although mirabegron
(50 mg) did not show statistically signiﬁcant superiority to placebo
in the change of mean number of urgency, urge incontinence, or
nocturia episodes, the changes of these variables in the mirabegron
arm were similar with those in other regional trials.
Although the change in QOL measurements after mirabegron
treatment did not show statistically signiﬁcant superiority to
Fig. 4. Comparison of efﬁcacy end points of the placebo and mirabegron (50 mg) arms among Taiwanese and Japan (JPN), Europe (Eu), and United States (U.S.) trials. *Indicates
signiﬁcant difference.
H.-C. Kuo et al. / Urological Science 26 (2015) 41e48 47placebo in all domain scores of QOL as assessed by the KHQ, all
domain scores were decreased after the treatment, which in-
dicates that a subjective improvement was experienced in Taiwa-
nese patients treated with mirabegron (50 mg). Moreover, the
incidence of most common TEAEs was similar to those in other
regional trials, which conﬁrmed the safety of mirabegron in OAB
treatment.
It is difﬁcult to explain why mirabegron (50 mg) shows the ef-
ﬁcacy only in reduction of daily frequency and increased volume
voided in Taiwanese people as well as in other regional trials, but
the placebo effect in the placebo arm was too high to result in a
signiﬁcant difference in other efﬁcacy end points between mir-
abegron and placebo. The most likely reason is the small case
number in this trial. Because the data are extracted from the Asian
trial, the case number of Taiwanese data might not be sufﬁcient for
a statistical signiﬁcance. It is also noteworthy that tolterodine
(4 mg) did not show any signiﬁcant difference to placebo in any
efﬁcacy variable. These results suggest that mirabegron has the
therapeutic efﬁcacy in treatment of OAB in Taiwanese people.
The placebo effect in this study is higher than that in the trials of
other regions.23e25 The reasons for the high placebo effect could be
including patients with a low urgency grade and high percentage of
patients having received antimuscarinic medication. In this trial,
we did not deﬁne OAB with a higher urgency grade (G3 or G4 in the
European Union and U.S. trials). Urgency should be the primary or
coprimary end point for future studies of OAB and detrusor over-
activity.28 However, younger patients and OAB dry patients might
have a higher incidence of bladder oversensitivity rather than
detrusor overactivity. Our previous study had shown that a higherurgency severity score recorded in conjunctionwith a voiding diary
and wet OAB was strongly associated with urodynamic detrusor
overactivity.29 It is possible that a considerably high percentage of
patients enrolled in this Taiwanese trial might not have true OAB. In
that case, the placebo effect increases. It should be noted that, as
seen in other studies of antimuscarinic agents, the placebo effect is
usually high in OAB clinical trials.30 In this study, > 75% of patients
had received medication for OAB previously. The high placebo ef-
fect might be due to speciﬁc characteristics of Taiwanese people
who have high expectations for the new test drug after failed
treatments with previous agents. This high placebo response
diminished the treatment effect seen with mirabegron in this
Taiwanese data.
It is also interesting to note that there is a poor tolterodine effect
in this Taiwanese data. None of the primary or secondary variables
were found to have signiﬁcantly superior effect to placebo in the
tolterodine arm. As stated earlier, in this study > 75% of patients
received drug medication for OAB previously, mainly anti-
muscarinic agents. It is not surprising that most patients who
agreed to participate in this mirabegron trial experienced treat-
ment failures with antimuscarinics, and therefore, did not show
response to the active treatment drug tolterodine.
5. Conclusion
Based on the results of this study conducted in Taiwan, it is
concluded that mirabegron at a dose of 50 mg once daily for 12
weeks is superior to placebo in reducing the frequency of mictu-
ritions and increasing the volume voided in patients with
H.-C. Kuo et al. / Urological Science 26 (2015) 41e4848symptoms of OAB. Mirabegron at a dose of 50 mg once daily for 12
weeks was safe and well tolerated. No clinically relevant AEs were
identiﬁed in patients with symptoms of OAB.
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Appendix 1. Inclusion and exclusion criteria.Inclusion criteria:
1. Symptoms of overactive bladder for at least 12 weeks before initiation of the
run-in period;
2. An average of  8 micturitions/24 hours; and
3. An average of  1 episode of urgency or urgency incontinence/24 hours,
during a 3-day micturition diary period
Exclusion criteria:
1. Stress urinary incontinence as a predominant symptom at screening;
2. Urinary tract infection, urinary stone, interstitial cystitis, or a history of
recurrent urinary tract infection;
3. Conﬁrmed postvoid residual volume of  100 mL or a clinically signiﬁcant
lower urinary tract obstructive disease;
4. An average total daily urine volume  3000 mL (as recorded in a 3-day
voiding diary period);
5. Uncontrolled hypertension (sitting systolic blood pressure  180 mmHg or
diastolic blood pressure  110 mmHg);
6. Pulse rate  110 beats per minute (bpm) or< 50 bpm; and
7. Patient has indwelling catheter or practices intermittent self-catheterization.References
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